Adapting CMC & Quality by Design for Individualised mRNA-LNP Therapies
11:30 am - Friday 19th February 2027
- Applying phase-appropriate CMC strategies to enable the efficient development and clinical translation of individualised mRNA-LNP therapies
- Leveraging Quality by Design (QbD) principles to build product and process understanding while maintaining flexibility for patient-specific treatments
- Addressing comparability, control strategy, and regulatory considerations in the evolving landscape of personalised medicines
